Merck Returns to Cardiome All Rights to Atrial Fibrillation Drug Vernakalant

Merck and Cardiome announced today that Merck is returning to Cardiome all marketing and development rights for the atrial fibrillation (AF) drug vern...

To continue reading, please log in to the right or request an invitation.